Analysis of the grouping effect and hospitalization cost of patients with malignant proliferative disease in a hospital under DRG payment
- VernacularTitle:DRG支付下某院恶性增生性疾患分组效果与住院费用分析
- Author:
Guiyuan XIANG
1
;
Yuanlin WU
1
;
Lanlan GAN
1
;
Shigeng CHEN
2
;
Yao LIU
1
Author Information
1. Dept. of Pharmacy，Army Medical Center of PLA，Chongqing 400042，China
2. Medical Insurance Office，Army Medical Center of PLA，Chongqing 400042，China
- Publication Type:Journal Article
- Keywords:
diagnosis-related group;
patients with malignant proliferative disease;
grouping effect;
hospitalization costs
- From:
China Pharmacy
2023;34(13):1637-1641
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To analyze the grouping effect and composition of hospitalization costs for cases of patients with malignant proliferative disease under the diagnosis-related group （DRG） payment system， as well as any changes， in order to provide a basis for medical institutions to improve DRG payment-related measures， control drug costs， and for relevant departments to make decisions. METHODS The data of patients with malignant proliferative disease cases were collected from a “Third Grade Class A” hospital in 2021 and 2022， and the variation coefficient （CV） was used to evaluate the grouping of DRG. The structural variation degree and the new grey correlation analysis were used to study the structural variation of hospitalization cost and the correlation degree between the hospitalization cost and the cost of other items. RESULTS The overall reduction in variance （RIV） for the DRG group of patients with malignant proliferative disease was 79.36%； the CV of other groups were all lower than one except that the RW21 group was 1.09. Compared with 2021， the hospitalization cost for patients with malignant proliferative disease in 2022 decreased by 17.80%， and the decreases in management fees and drug costs were 32.15% and 21.30%， respectively， while the per capita medical expenses increased by 17.26%. The new grey correlation degree of drug cost decreased， but that of medical expenses increased. CONCLUSIONS Under the DRG payment system， hospitalization costs for patients with malignant proliferative disease in the sample hospital decrease， but the grouping efficiency of RW21 and other disease groups needs improvement， and the cost structure needs optimization.
